AR037491A1 - Bromuro de (1alfa,2beta,4beta,5alfa,7beta,)-7-[(hidroxi-di-2tienil-acetil)oxi]-9,9-dimetil-3-oxa-9-azoniatriciclo.[3.3.1.0 /2,4]-nonano cristalino en la forma anhidra (bromuro de tiotropio cristalino anhidro) , un procedimiento para su preparacion , su utilizacion para la preparacion de un medicamen - Google Patents

Bromuro de (1alfa,2beta,4beta,5alfa,7beta,)-7-[(hidroxi-di-2tienil-acetil)oxi]-9,9-dimetil-3-oxa-9-azoniatriciclo.[3.3.1.0 /2,4]-nonano cristalino en la forma anhidra (bromuro de tiotropio cristalino anhidro) , un procedimiento para su preparacion , su utilizacion para la preparacion de un medicamen

Info

Publication number
AR037491A1
AR037491A1 ARP020102337A ARP020102337A AR037491A1 AR 037491 A1 AR037491 A1 AR 037491A1 AR P020102337 A ARP020102337 A AR P020102337A AR P020102337 A ARP020102337 A AR P020102337A AR 037491 A1 AR037491 A1 AR 037491A1
Authority
AR
Argentina
Prior art keywords
preparation
crystal
bromide
tiotropium bromide
oxa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased/Invalidation/Refusal/Rejection/Nullification
Application number
ARP020102337A
Other languages
English (en)
Inventor
Sieger Peter Dr
Ulrike Werthmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR037491A1 publication Critical patent/AR037491A1/es
Ceased/Invalidation/Refusal/Rejection/Nullification legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Bromuro de (1a,2b,4b,5a,7b)-7-[(hidroxi-di-2-tienil-acetil)oxi]-9,9-dimetil-3-oxa-9-azoniatriciclo- [3.3.1.02,4]-nonano cristalino en la forma anhidra (bromuro de tiotropio cristalino anhidro), de fórmula (1). Está modificación cristalina anhidra del bromuro de tiotropio no tiene tendencia a la formación de polimorfos, es uniforme y claramente definida. Es un agente anticolinérgico muy eficaz y, por lo tanto, es útil en la terapia del asma o de la COPD ( enfermedad pulmonar obstructiva crónica). También se describe un procedimiento para preparar el bromuro de tiotropio cristalino anhidro por desecación del monohidrato de bromuro de tiotropio cristalino, la utilización del bromuro de tiotropio cristalino anhidro para preparar un medicamento destinado al tratamiento de enfermedades en las que la aplicación de un agente anticolinérgico puede desarrollar una utilidad terapéutica, y un medicamento, en particular un polvo inhalable, que contiene bromuro de tiotropio anhidro cristalino.
ARP020102337A 2001-06-22 2002-06-21 Bromuro de (1alfa,2beta,4beta,5alfa,7beta,)-7-[(hidroxi-di-2tienil-acetil)oxi]-9,9-dimetil-3-oxa-9-azoniatriciclo.[3.3.1.0 /2,4]-nonano cristalino en la forma anhidra (bromuro de tiotropio cristalino anhidro) , un procedimiento para su preparacion , su utilizacion para la preparacion de un medicamen Ceased/Invalidation/Refusal/Rejection/Nullification AR037491A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10129710 2001-06-22
DE10215436 2002-04-08

Publications (1)

Publication Number Publication Date
AR037491A1 true AR037491A1 (es) 2004-11-17

Family

ID=26009556

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102337A Ceased/Invalidation/Refusal/Rejection/Nullification AR037491A1 (es) 2001-06-22 2002-06-21 Bromuro de (1alfa,2beta,4beta,5alfa,7beta,)-7-[(hidroxi-di-2tienil-acetil)oxi]-9,9-dimetil-3-oxa-9-azoniatriciclo.[3.3.1.0 /2,4]-nonano cristalino en la forma anhidra (bromuro de tiotropio cristalino anhidro) , un procedimiento para su preparacion , su utilizacion para la preparacion de un medicamen

Country Status (38)

Country Link
EP (1) EP1401445B1 (es)
JP (1) JP2005504015A (es)
KR (2) KR101011353B1 (es)
CN (1) CN100586948C (es)
AR (1) AR037491A1 (es)
AT (1) ATE337006T1 (es)
AU (1) AU2002345016B2 (es)
BG (1) BG66303B1 (es)
BR (1) BR0210537A (es)
CA (1) CA2450961C (es)
CO (1) CO5550423A2 (es)
CY (1) CY1105223T1 (es)
CZ (1) CZ302786B6 (es)
DE (1) DE50207943D1 (es)
DK (1) DK1401445T3 (es)
EA (1) EA005813B1 (es)
EE (1) EE05316B1 (es)
EG (1) EG24851A (es)
ES (1) ES2271280T3 (es)
HK (1) HK1068540A1 (es)
HR (1) HRP20031066B1 (es)
HU (1) HUP0400333A3 (es)
IL (2) IL159238A0 (es)
ME (1) ME00412B (es)
MX (1) MXPA03011718A (es)
MY (1) MY122779A (es)
NO (1) NO334301B1 (es)
NZ (1) NZ530690A (es)
PE (2) PE20081305A1 (es)
PL (1) PL208137B1 (es)
PT (1) PT1401445E (es)
RS (1) RS50441B (es)
SA (1) SA02230255B1 (es)
SI (1) SI1401445T1 (es)
SK (1) SK287262B6 (es)
TW (2) TW200617007A (es)
UY (1) UY27342A1 (es)
WO (1) WO2003000265A1 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10212264A1 (de) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
ES2338563T3 (es) * 2003-11-03 2010-05-10 Boehringer Ingelheim International Gmbh Nuevo anhidrato cristalino con efecto anticolinergico.
DE102004016179A1 (de) * 2004-03-30 2005-10-20 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von proliferativen Prozessen
JP2007533683A (ja) 2004-04-22 2007-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系疾患治療用のベンゾオキサジン含有医薬組成物
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
DE102004024454A1 (de) 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE602004020337D1 (de) 2004-08-11 2009-05-14 Boehringer Ingelheim Pharma Anticholinergika enthaltende Arzneimittel zur Behandlung von Krankheiten der ableitenden Harnwege
US20060079544A1 (en) * 2004-08-13 2006-04-13 Boehringer Ingelheim International Gmbh Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic
DE102004048389A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Modifizierung von Oberflächen von Laktose als Hilfsstoff zur Verwendung für Pulverinhalativa
NZ563448A (en) 2005-04-28 2011-01-28 Boehringer Ingelheim Int Benzofuranone derivatives for treating inflammatory diseases
BRPI0611091A2 (pt) * 2005-05-02 2010-08-03 Boehringer Ingelheim Int formas cristalinas de brometo de tiotrópico
PL1881980T3 (pl) * 2005-05-02 2013-01-31 Boehringer Ingelheim Int Nowe krystaliczne formy bromku tiotropium
DE102005030733A1 (de) 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
CN101208316B (zh) 2005-08-15 2012-05-09 贝林格尔·英格海姆国际有限公司 制备β-模拟物的方法
US20070086957A1 (en) 2005-10-10 2007-04-19 Thierry Bouyssou Combination of medicaments for the treatment of respiratory diseases
US7423146B2 (en) 2005-11-09 2008-09-09 Boehringer Ingelheim International Gmbh Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones
US9108962B2 (en) 2005-12-19 2015-08-18 Sicor, Inc. Forms of tiotropium bromide and processes for preparation thereof
ES2396978T5 (es) * 2005-12-19 2015-12-04 Sicor, Inc. Forma cristalina novedosa de bromuro de tiotropio y procedimiento para la preparación de la misma
CN100999521B (zh) * 2006-01-13 2010-12-08 江苏正大天晴药业股份有限公司 结晶性抗胆碱药噻托溴铵
EA013108B1 (ru) 2006-04-19 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Дигидротиенопиримидины для лечения воспалительных заболеваний
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
US20090324510A1 (en) 2006-08-07 2009-12-31 Boehringer Ingelheim International Gmbh Drug combinations for the treatment of respiratory tract diseases
PE20080610A1 (es) 2006-08-22 2008-07-15 Boehringer Ingelheim Int Nuevos beta-agonistas enantiomericamente puros, procedimientos para su preparacion y uso como medicamentos
GB0716026D0 (en) 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
EP2380891B1 (de) 2007-10-19 2013-12-11 Boehringer Ingelheim International Gmbh Substituierte Piperidino-Dihydrothienopyrimidine
EP2093219A1 (de) 2008-02-22 2009-08-26 Boehringer Ingelheim International Gmbh Kristalline, enantiomerenreine Salzform eines Betamimetikums und dessen Verwendung als Arzneimittel
ES2551557T3 (es) 2008-12-19 2015-11-19 Boehringer Ingelheim International Gmbh Pirimidin-4-carboxamidas cíclicas como antagonistas del receptor CCR2 para el tratamiento de inflamaciones, asma y EPOC
WO2010101538A2 (en) 2009-03-06 2010-09-10 Bilgic Mahmut New crystal forms
US20130143905A1 (en) 2009-12-17 2013-06-06 Boehringer Ingelheim International Gmbh Novel antagonists for ccr2 and uses thereof
CN102933579B (zh) 2009-12-17 2015-07-15 贝林格尔.英格海姆国际有限公司 新的ccr2受体拮抗剂及其用途
CA2786245A1 (en) 2010-01-29 2011-08-04 Boehringer Ingelheim International Gmbh Substituted naphthyridines and their use as syk kinase inhibitors
US8877745B2 (en) 2010-05-12 2014-11-04 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011141477A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2571870B1 (en) 2010-05-17 2015-01-21 Boehringer Ingelheim International GmbH Ccr2 antagonists and uses thereof
EP2576542B1 (en) 2010-05-25 2015-04-22 Boehringer Ingelheim International GmbH Cyclic amide derivatives of pyridazine-3-carboxylic acids and their use in the treatment of pulmonary, pain, immune related and cardiovascular diseases
WO2011151251A1 (en) 2010-06-01 2011-12-08 Boehringer Ingelheim International Gmbh New ccr2 antagonists
TR201007108A2 (tr) * 2010-08-25 2012-03-21 B�Lg�� Mahmut Yeni tiotropyum bromür kristali ve üretim yöntemi.@
WO2012101013A1 (en) 2011-01-28 2012-08-02 Boehringer Ingelheim International Gmbh Substituted pyridinyl-pyrimidines and their use as medicaments
TR201101897A2 (tr) 2011-02-28 2012-09-21 Bi̇lgi̇ç Mahmut Tiotropyum bromür içeren kristal madde
TR201111589A2 (tr) * 2011-03-03 2012-09-21 Bi̇lgi̇ç Mahmut Tiotropyum bromür susuz kristal formu.
TR201102068A2 (tr) 2011-03-03 2012-09-21 Bi̇lgi̇ç Mahmut Tiotropyum bromür içeren kristal maddeler
WO2012171863A1 (en) 2011-06-16 2012-12-20 Boehringer Ingelheim International Gmbh New selective ccr2 antagonists
EP2731941B1 (en) 2011-07-15 2019-05-08 Boehringer Ingelheim International GmbH Novel and selective ccr2 antagonists
JP5860960B2 (ja) 2011-07-26 2016-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換キノリン類及び医薬としてのそれらの使用
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
RS57945B1 (sr) 2011-11-25 2019-01-31 Adverio Pharma Gmbh Postupak za dobijanje supstituisanih 5-fluoro-1h-pirazolopiradina
CZ304368B6 (cs) 2011-11-28 2014-04-02 Zentiva, K.S. Směsný solvát tiotropium bromidu a způsob jeho přípravy
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
PT106142B (pt) * 2012-02-10 2014-07-18 Hovione Farmaci Ncia S A Processo para a preparação de brometo de tiotrópio
US9096579B2 (en) 2012-04-20 2015-08-04 Boehringer Ingelheim International Gmbh Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
WO2014042605A1 (en) * 2012-09-11 2014-03-20 Mahmut Bilgic New tiotropium bromide crystalline form
DK2914593T3 (en) 2012-11-05 2017-04-18 Zentiva Ks STABILIZATION OF TIOTROPIUM SOLVATES
CN104341412A (zh) * 2013-07-29 2015-02-11 天津金耀集团有限公司 一种无水噻托溴铵结晶的制备方法
JP6599884B2 (ja) 2014-03-19 2019-10-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規なヘテロアリール化合物及び医薬としてのその使用
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
SG11201702980QA (en) 2014-10-21 2017-05-30 Ariad Pharma Inc Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine
EP3414243A1 (en) * 2016-02-11 2018-12-19 Sima Patent Ve Lisanslama Hizmetleri Ltd. STI Crystalline form of tiotropium bromide anhydrate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931041C2 (de) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
HU226830B1 (en) * 2000-10-12 2009-11-30 Boehringer Ingelheim Pharma Thiotropium bromide monohydrate, method for producing the same and a pharmaceutical composition containing the same
DE10064816A1 (de) * 2000-12-22 2002-06-27 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Anticholinergikums

Also Published As

Publication number Publication date
EA005813B1 (ru) 2005-06-30
PT1401445E (pt) 2006-10-31
HRP20031066A2 (en) 2004-04-30
YU99703A (sh) 2006-05-25
PL364489A1 (en) 2004-12-13
KR20040018285A (ko) 2004-03-02
EE05316B1 (et) 2010-08-16
HUP0400333A2 (hu) 2004-12-28
EG24851A (en) 2010-10-27
CN100586948C (zh) 2010-02-03
BG108440A (en) 2004-08-31
HRP20031066B1 (en) 2011-10-31
DK1401445T3 (da) 2006-11-27
SA02230255B1 (ar) 2006-10-31
EA200301293A1 (ru) 2004-08-26
KR100971616B1 (ko) 2010-07-22
EP1401445A1 (de) 2004-03-31
IL159238A (en) 2010-04-15
RS50441B (sr) 2010-03-02
TWI261589B (en) 2006-09-11
KR20090031638A (ko) 2009-03-26
MEP62008A (en) 2011-05-10
PE20081305A1 (es) 2008-10-01
CA2450961C (en) 2010-03-30
CZ302786B6 (cs) 2011-11-09
AU2002345016B2 (en) 2008-04-17
JP2005504015A (ja) 2005-02-10
SI1401445T1 (sl) 2007-02-28
SK287262B6 (sk) 2010-04-07
HK1068540A1 (en) 2005-04-29
BG66303B1 (bg) 2013-03-29
EE200400029A (et) 2004-04-15
WO2003000265A1 (de) 2003-01-03
EP1401445B1 (de) 2006-08-23
CZ2004120A3 (cs) 2004-05-12
NZ530690A (en) 2005-05-27
MY122779A (en) 2006-05-31
ES2271280T3 (es) 2007-04-16
PL208137B1 (pl) 2011-03-31
NO20035696D0 (no) 2003-12-19
NO334301B1 (no) 2014-02-03
CY1105223T1 (el) 2010-03-03
PE20030130A1 (es) 2003-04-02
CN1520294A (zh) 2004-08-11
UY27342A1 (es) 2003-02-28
DE50207943D1 (de) 2006-10-05
ME00412B (me) 2011-10-10
TW200617007A (en) 2006-06-01
IL159238A0 (en) 2004-06-01
CO5550423A2 (es) 2005-08-31
ATE337006T1 (de) 2006-09-15
SK522004A3 (en) 2004-06-08
KR101011353B1 (ko) 2011-01-28
BR0210537A (pt) 2004-06-22
MXPA03011718A (es) 2004-12-06
CA2450961A1 (en) 2003-01-03
HUP0400333A3 (en) 2012-10-29

Similar Documents

Publication Publication Date Title
AR037491A1 (es) Bromuro de (1alfa,2beta,4beta,5alfa,7beta,)-7-[(hidroxi-di-2tienil-acetil)oxi]-9,9-dimetil-3-oxa-9-azoniatriciclo.[3.3.1.0 /2,4]-nonano cristalino en la forma anhidra (bromuro de tiotropio cristalino anhidro) , un procedimiento para su preparacion , su utilizacion para la preparacion de un medicamen
NO20063047L (no) Vandige ciclesonidsuspensjoner for forstoving
SE0104340D0 (sv) New compounds
TW200745111A (en) New compounds
SE0200979D0 (sv) New compounds
IL164373A (en) Benzamide derivatives, pharmaceutical compositions containing them, process for their preparation and use thereof in the manufacture of medicaments and as medicaments in the treatment of diseases associated with cancer
DE60318193D1 (en) Phenethanolaminderivate
IL158589A (en) Carboxylic acid substituted oxazole derivatives, process for their manufacture, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment and prophylaxis of diseases which are modulated by ppar-alpha and -gamma activators
MEP36608A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
EA200401005A1 (ru) Дозированные ингаляторы под давлением, содержащие растворы бета-2-агонистов
MY129422A (en) Medicinal compounds
ATE330585T2 (de) Behandlung von atemerkrankungen
ATE365720T1 (de) Agonisten von beta-adrenorezeptoren
RU2004122921A (ru) Композиция для ингаляции
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
CO5550426A2 (es) Novedoso metodo terapeutico
ECSP066545A (es) Procedimiento para la preparación de sales de tiotropio, sales de tiotropio, así como formulaciones medicamentosas que las contienen
TW200606164A (en) New compounds
HUP0401201A2 (hu) Flibanserin stabil polimorfja, ipari eljárás előállítására és alkalmazása gyógyszerek előállítására
SE0100569D0 (sv) New compounds
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
TW200800984A (en) New compounds
SE0102440D0 (sv) New compound
JP2010500284A5 (es)
BRPI0409380A (pt) composições farmacêuticas

Legal Events

Date Code Title Description
FC Refusal